GlassScriptPhysician profile
Mohina Gupta
NPI 1174578843
$1,109.70
in general payments reported to CMS, 2019-2025
21 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.12 · 2020: $141 · 2021: $78.14 · 2022: $212 · 2023: $142 · 2024: $273 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.65 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $227.14 | 2022-2025 | Kisunla, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $200.26 | 2019-2024 | Airsupra, Breztri |
| Pfizer INC. | $92.47 | 2019-2025 | |
| Abbvie INC. | $83.92 | 2021-2024 | |
| Novo Nordisk INC | $75.00 | 2021-2024 | Rybelsus, Ozempic |
| Abbott Laboratories | $53.72 | 2022-2025 | Freestyle Libre 3 |
| Philips North America LLC | $52.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.47 | 2024-2025 | Jardiance |
| Allergan, INC. | $37.98 | 2019-2020 | |
| Exact Sciences Corporation | $37.32 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $28.80 | 2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $25.17 | 2022 | |
| Amarin Pharma, INC. | $22.99 | 2020 | |
| Glaxosmithkline, LLC. | $20.30 | 2020 | |
| Averitas Pharma INC. | $19.05 | 2023 | Qutenza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $18.32 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.11 | 2024 | Spravato |
| Xeris Pharmaceuticals, INC. | $15.89 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.32 | 2024 | Voquezna |
| Evoke Pharma, INC. | $13.41 | 2022 | |
| Currax Pharmaceuticals LLC | $13.23 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohina Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.